Jianping Ning

Jianping Ning

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2018 in Journal of Materials Science: Materials in Medicine
Verified
Journal Article
Closed access
PDF file
XFXiao Fu
Xiao Fu
JNJianping Ning
Jianping Ning

4 April 2019 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
YDYanling Dai
Yanling Dai
SDSiyuan Dai
Siyuan Dai
XXXiaohui Xie
Xiaohui Xie
JNJianping Ning
Jianping Ning
Systemic anticoagulation is not suitable for hemodialysis (HD) patients with a high risk of bleeding in the clinic. An HD membrane that provides a localized anticoagulation membrane surface may be a promising strategy to solve this intractable problem for HD patients. Herein, we modified a nonthrombogenic polyethersulfone (PES) dialyzer membrane by grafting argatroban (AG) and methoxy polyethylene glycol amine (mPEG-NH2) via a polydopamine (PDA) strategy. The PES substrates were immersed in an alkaline dopamine solution for 24 h, and then, AG and mPEG-NH2 were sequentially grafted covalently onto the resultant membrane. Attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR) and X-ray photoelectron spectroscopy (XPS) were utilized to confirm the successful introduction of PDA and the immobilization of AG and mPEG-NH2. Scanning electron microscopy (SEM) and atomic force microscopy (AFM) were used to observe the surface structure and morphology after the surface modification. The excellent antithrombotic abilities of the modified membrane were demonstrated by the suppression of platelet adhesion and activation, prolongation of clotting times, and inhibition of thrombin generation and complement activation. This work describes an efficient and convenient method to immobilize AG and mPEG-NH2 to create a nonthrombogenic biointerface for blood-contacting devices such as HD membranes.

2 November 2015 in RSC Advances
Verified
Journal Article
Closed access
PDF file
SFShuang-Shuang Fu
Shuang-Shuang Fu
JNJianping Ning
Jianping Ning
XLXiao-Hua Liao
Xiao-Hua Liao
XFXiao Fu
Xiao Fu
ZYZheng-Bo Yang
Zheng-Bo Yang
Systemic anticoagulation is indispensable for hemodialysis patients to prevent clotting, but patients at high risk of bleeding cannot be given systemic anticoagulation. Hemodialyzer membrane modification maybe an effective program to solve this problem. In this study, we chose argatroban, a direct thrombin inhibitor, to modify a polyethersulfone (PES) membrane. Firstly, we prepared an argatroban (AG) grafted polyethersulfone (PES-AG) matrix by acetylating, oxidating and amidation reactions. Then, PES-AG was blended with PES at ratios of 2 : 1 and 1 : 1 respectively to prepare a PES/PES-AG membrane by using a phase inversion technique. FTIR and 1H NMR spectroscopy were used to confirm that argatroban was grafted to PES successfully. Scanning electron microscopy (SEM) was used to observe the characteristic morphology of the membranes. Activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT) and platelet function were detected to evaluate the antithrombotic property of the modified membrane. The results indicate that the antithrombotic property of the PES/PES-AG (1 : 1) membrane was superior to other three groups.

11 November 2015 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
XFXiao Fu
Xiao Fu
QCQin-Qin Cui
Qin-Qin Cui
JNJianping Ning
Jianping Ning
SFShuang-Shuang Fu
Shuang-Shuang Fu
XLXiao-Hua Liao
Xiao-Hua Liao
BACKGROUND:High- and low-flux hemodialysis (HFHD and LFHD, respectively) are dialysis procedures designed to eliminate blood toxins that accumulate in end-stage renal disease. HFHD may reduce vascular calcification by removing serum fibroblast growth...

12 August 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
JYJiayi Yang
Jiayi Yang
LPLi Peng
Li Peng
YTYuqiu Tian
Yuqiu Tian
WTwenbin tang
wenbin tang
LPLinlin Peng
Linlin Peng
YPYun Peng
Yun Peng
Diabetic nephropathy (DN) is the most important cause of end-stage renal disease with a poorer prognosis and high economic burdens of medical treatments. It is of great research value and clinical significance to explore potential gene targets of renal tubulointerstitial lesions in DN. To properly identify key genes associated with tubulointerstitial injury of DN, we initially performed a weighted gene coexpression network analysis of the dataset to screen out two nonconserved gene modules (dark orange and dark red). The regulation of oxidative stress-induced intrinsic apoptotic signaling pathway, PI3K-Akt signaling pathway, p38MAPK cascade, and Th1 and Th2 cell differentiation were primarily included in Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of these two modules. Next, 199 differentially expressed genes (DEGs) were identified via the limma package. Then, the GO annotation and KEGG pathways of the DEGs were primarily enriched in extracellular matrix (ECM) organization, epithelial cell migration, cell adhesion molecules (CAMs), NF-kappa B signaling pathway, and ECM-receptor interaction. Gene set enrichment analysis showed that in the DN group, the interaction of ECM-receptor, CAMs, the interaction of cytokine-cytokine receptor, and complement and coagulation cascade pathways were significantly activated. Eleven key genes, including ALB, ANXA1, ANXA2, C3, CCL2, CLU, EGF, FOS, PLG, TIMP1, and VCAM1, were selected by constructing a protein-protein interaction network, and expression validation, ECM-related pathways, and glomerular filtration rate correlation analysis were performed in the validated dataset. The upregulated expression of hub genes ANXA2 and FOS was verified by real-time quantitative PCR in HK-2 cells treated with high glucose. This study revealed potential regulatory mechanisms of renal tubulointerstitial damage and highlighted the crucial role of extracellular matrix in DN, which may promote the identification of new biomarkers and therapeutic targets.

28 February 2020
Verified
Journal Article
Closed access
XXXiaohui Xie
Xiaohui Xie
SDSiyuan Dai
Siyuan Dai
YDYanling Dai
Yanling Dai
JNJianping Ning
Jianping Ning